CD8A and neoplasm: Interestingly, intravenous BCG treatment has resulted in increased CD8+ T cells and reduced myeloid-derived suppressor cells (MDSCs), while intravesical BCG, although FDA-approved for high-risk non-muscle-invasive bladder cancer, has been shown to promote tumor-support TME (Atallah et al., 2024).